Actively Recruiting
Phase 2 Study of Avutometinib and Defactinib for Treating RAF Dimer-Driven Radioiodine-Refractory Differentiated and Anaplastic Thyroid Cancer
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-06-22
30
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the combination of avutometinib and defactinib as a treatment for patients with RAF dimer-driven radioiodine-refractory differentiated thyroid cancer or anaplastic thyroid cancer. This phase II study aims to assess whether this combination is effective and safe, causing few or mild side effects. The trial is sponsored by Memorial Sloan Kettering Cancer Center and funded by the FDA Office of Orphan Products Development. Participants receive avutometinib at 3.2 mg twice weekly and defactinib at 200 mg twice daily, both given in cycles of 3 weeks on treatment followed by 1 week off. There are two patient groups one with radioiodine-refractory, recurrent or metastatic differentiated thyroid cancer, and the other with anaplastic thyroid cancer. Both groups are treated similarly with this drug combination throughout the study period. During the study, participants undergo assessments to measure tumor response using the overall response rate over up to two years. They will have biopsies and provide tumor tissue for correlative studies. Safety and side effects are monitored, including heart function tests and laboratory evaluations. The total study duration for each participant can last up to two years, with regular visits for treatment and evaluation.
CONDITIONS
Brief Title
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Research Team
A
Alan Ho, MD, PhD
E
Eric Sherman, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
